These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 2060176)

  • 41. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.
    Smith MR; McGovern FJ; Zietman AL; Fallon MA; Hayden DL; Schoenfeld DA; Kantoff PW; Finkelstein JS
    N Engl J Med; 2001 Sep; 345(13):948-55. PubMed ID: 11575286
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment with pamidronate for osteoporosis complicating long-term intestinal failure.
    Pastore S; Londero M; Barbieri F; Di Leo G; Paparazzo R; Ventura A
    J Pediatr Gastroenterol Nutr; 2012 Nov; 55(5):615-8. PubMed ID: 22614111
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Use of bisphosphonates and dual-energy X-ray absorptiometry scans in the prevention and treatment of glucocorticoid-induced osteoporosis in rheumatology.
    Wall E; Walker-Bone K
    QJM; 2008 Apr; 101(4):317-23. PubMed ID: 18270228
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study.
    McCloskey E; Selby P; Davies M; Robinson J; Francis RM; Adams J; Kayan K; Beneton M; Jalava T; Pylkkänen L; Kenraali J; Aropuu S; Kanis JA
    J Bone Miner Res; 2004 May; 19(5):728-36. PubMed ID: 15068495
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Young adults with juvenile arthritis in remission attain normal peak bone mass at the lumbar spine and forearm.
    Haugen M; Lien G; Flatø B; Kvammen J; Vinje O; Sørskaar D; Førre O
    Arthritis Rheum; 2000 Jul; 43(7):1504-10. PubMed ID: 10902752
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Fluoride treatment: a good choice in osteoporosis].
    Duursma SA; Raymakers JA
    Ned Tijdschr Geneeskd; 1998 Aug; 142(34):1915-9. PubMed ID: 9856178
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A 4-year treatment with clodronate plus calcium and vitamin D supplements does not improve bone mass in primary biliary cirrhosis.
    Floreani A; Carderi I; Ferrara F; Rizzotto ER; Luisetto G; Camozzi V; Baldo V
    Dig Liver Dis; 2007 Jun; 39(6):544-8. PubMed ID: 17416215
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bone health and growth in glucocorticoid-treated patients with juvenile idiopathic arthritis.
    Valta H; Lahdenne P; Jalanko H; Aalto K; Mäkitie O
    J Rheumatol; 2007 Apr; 34(4):831-6. PubMed ID: 17309121
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of tiludronate on bone loss in paraplegic patients.
    Chappard D; Minaire P; Privat C; Berard E; Mendoza-Sarmiento J; Tournebise H; Basle MF; Audran M; Rebel A; Picot C
    J Bone Miner Res; 1995 Jan; 10(1):112-8. PubMed ID: 7747617
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pamidronate after heart transplantation.
    Tüzün S
    Osteoporos Int; 2002 Sep; 13(9):762. PubMed ID: 12349830
    [No Abstract]   [Full Text] [Related]  

  • 51. Therapeutic Treatments for Osteoporosis-Which Combination of Pills Is the Best among the Bad?
    Tonk CH; Shoushrah SH; Babczyk P; El Khaldi-Hansen B; Schulze M; Herten M; Tobiasch E
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163315
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Drug Treatment of Low Bone Mass and Other Bone Conditions in Pediatric Patients.
    Costi S; Giani T; Orsini F; Cimaz R
    Paediatr Drugs; 2022 Mar; 24(2):103-119. PubMed ID: 35013997
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Protecting Bone Health in Pediatric Rheumatic Diseases: Pharmacological Considerations.
    Zhang Y; Milojevic D
    Paediatr Drugs; 2017 Jun; 19(3):193-211. PubMed ID: 28290112
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bisphosphonate therapy for children and adolescents with secondary osteoporosis.
    Ward L; Tricco AC; Phuong P; Cranney A; Barrowman N; Gaboury I; Rauch F; Tugwell P; Moher D
    Cochrane Database Syst Rev; 2007 Oct; 2007(4):CD005324. PubMed ID: 17943849
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cyclic intravenous pamidronate treatment in children with nodulosis, arthropathy and osteolysis syndrome.
    Al-Mayouf SM; Madi SM; Bin-Abbas BS
    Ann Rheum Dis; 2006 Dec; 65(12):1672-3. PubMed ID: 17105860
    [No Abstract]   [Full Text] [Related]  

  • 56. Systematic review of effectiveness of bisphosphonates in treatment of low bone mineral density and fragility fractures in juvenile idiopathic arthritis.
    Thornton J; Ashcroft DM; Mughal MZ; Elliott RA; O'Neill TW; Symmons D
    Arch Dis Child; 2006 Sep; 91(9):753-61. PubMed ID: 16690698
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pamidronate treatment of pediatric fracture patients on chronic steroid therapy.
    Acott PD; Wong JA; Lang BA; Crocker JF
    Pediatr Nephrol; 2005 Mar; 20(3):368-73. PubMed ID: 15690187
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The role of bisphosphonates in diseases of childhood.
    Srivastava T; Alon US
    Eur J Pediatr; 2003 Nov; 162(11):735-51. PubMed ID: 14523647
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intravenous pamidronate in juvenile osteoporosis.
    Shaw NJ; Boivin CM; Crabtree NJ
    Arch Dis Child; 2000 Aug; 83(2):143-5. PubMed ID: 10906023
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bone mineral density in children with juvenile chronic arthritis.
    Cetin A; Celiker R; Dinçer F; Ariyürek M
    Clin Rheumatol; 1998; 17(6):551-3. PubMed ID: 9890693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.